Boldt Joachim, Brosch Christian, Ducke Michael, Papsdorf Michael, Lehmann Andreas
Department of Anesthesiology and Intensive Care Medicine, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany.
Crit Care Med. 2007 Dec;35(12):2740-6. doi: 10.1097/01.CCM.0000288101.02556.DE.
There is continuing concern about the influence of hydroxyethylstarch on renal function in patients with compromised kidney function.
Prospective, randomized, single-center study.
University-affiliated hospital.
Fifty patients undergoing elective, first-time coronary artery bypass grafting using cardiopulmonary bypass with a preoperative serum creatinine between 1.5 and 2.5 mg/dL.
According to a prospective, randomized sequence, the patients received either hydroxyethylstarch with a low molecular weight (mean molecular weight 130 kD) and a low molar substitution (0.4) (6% hydroxyethylstarch 130/0.4) (n = 25) or 5% human albumin (n = 25). Volume was added to the priming (500 mL) and given perioperatively until the second postoperative day to keep pulmonary artery occlusion pressure or central venous pressure between 12 and 14 mm Hg.
Serum creatinine and cystatin plasma levels were measured from arterial blood samples. From urine specimens, N-acetyl-beta-D-glucosaminidase, glutathione transferase-alpha, and neutrophil gelatinase-associated lipocalin were measured. Measurements were performed after induction of anesthesia, at the end of surgery, 5 hrs after surgery, and on the first and second postoperative days. A follow-up after discharge from the hospital (60 days) was also done. Similar amounts of hydroxyethylstarch and albumin were infused. Serum creatinine, glomerular filtration rate, and cystatin C plasma levels were without significant differences between the groups. Concentrations of kidney-specific proteins were elevated at baseline and increased significantly after surgery without showing group differences. Urinary levels of neutrophil gelatinase-associated lipocalin increased more in the albumin- than in the hydroxyethylstarch-treated patients. None of the patients developed acute renal failure requiring renal replacement therapy during the hospital stay and thereafter.
A hydroxyethylstarch preparation with a low molecular weight and a low molar substitution given in cardiac surgery patients with preoperative compromised kidney function did not negatively influence kidney integrity compared with a human albumin-based volume replacement strategy.
肾功能受损患者中,羟乙基淀粉对肾功能的影响一直备受关注。
前瞻性、随机、单中心研究。
大学附属医院。
50例择期首次接受冠状动脉搭桥术且使用体外循环的患者,术前血清肌酐水平在1.5至2.5mg/dL之间。
按照前瞻性随机序列,患者接受低分子量(平均分子量130kD)和低摩尔取代度(0.4)的羟乙基淀粉(6%羟乙基淀粉130/0.4)(n = 25)或5%人血白蛋白(n = 25)。向预充液中加入一定量液体(500mL),并在围手术期给予直至术后第二天,以维持肺动脉闭塞压或中心静脉压在12至14mmHg之间。
从动脉血样本中测量血清肌酐和胱抑素血浆水平。从尿液标本中测量N - 乙酰 - β - D - 氨基葡萄糖苷酶、谷胱甘肽转移酶 - α和中性粒细胞明胶酶相关脂质运载蛋白。在麻醉诱导后、手术结束时、术后5小时以及术后第一和第二天进行测量。出院后(60天)也进行了随访。羟乙基淀粉和白蛋白的输注量相似。两组之间血清肌酐、肾小球滤过率和胱抑素C血浆水平无显著差异。肾脏特异性蛋白浓度在基线时升高,术后显著增加,但未显示出组间差异。白蛋白治疗组患者中性粒细胞明胶酶相关脂质运载蛋白的尿水平升高幅度大于羟乙基淀粉治疗组患者。住院期间及之后,无一例患者发生需要肾脏替代治疗的急性肾衰竭。
在术前肾功能受损的心脏手术患者中,给予低分子量和低摩尔取代度的羟乙基淀粉制剂,与基于人血白蛋白的容量替代策略相比,对肾脏完整性没有负面影响。